|Assessment Status||Rapid Review complete|
|Indication||Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.|
|Rapid review commissioned||15/06/2012|
|Rapid review completed||28/06/2012|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.